Pfizer has reported strong financial results for the third quarter, exceeding earnings estimates and raising its full-year guidance, largely driven by heightened demand for its COVID-19 treatment, Paxlovid. The company anticipates $10 billion in revenue from COVID products in 2024, prompting a revenue outlook increase of $1.5 billion. Despite these positive developments, Pfizer faces ongoing scrutiny from activist investor Starboard, which questions the sustainability of its growth and performance. CEO Albert Bourla defended the company’s turnaround strategy, aiming to quell investor concerns after recent criticisms. Amid strong sales, some analysts note that investor sentiment remains cautious, reflecting broader challenges in the market.